Connor, Clark & Lunn Investment Management (CC&L)
GRTX

Connor, Clark & Lunn Investment Management (CC&L)’s Galera Therapeutics, Inc. Common Stock GRTX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio GRTX Stock Details GRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-87,550
Closed -$273K – 1590
2023
Q2 		$273K Buy
+87,550
New +$260K ﹤0.01% 1126

Other funds holding GRTX

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s GRTX Position: Q3 2023 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Galera Therapeutics, Inc. Common Stock (GRTX) in Q3 2023, closing a stake of 87,550 shares — an estimated $273K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in GRTX in Q2 2023 and held it in 1 quarter. The position peaked at $273K in Q2 2023. 38 funds tracked by Wall St. Rank hold GRTX as of Q3 2023.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Galera Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 87,550 Galera Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $273K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Galera Therapeutics, Inc. Common Stock in Q2 2023 and held it in 1 quarter.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Galera Therapeutics, Inc. Common Stock position peaked at $273K in Q2 2023.
  • 38 funds tracked by Wall St. Rank held Galera Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q3 2023, filed 13 Nov 2023.